A systemically administered detoxified TLR4 agonist displays potent antitumor activity and an acceptable tolerance profile in preclinical models.
adjuvant effect
in vivo antitumor activity
lipopolysaccharides
liposomal formulation
modified TLR4 agonist
tolerance
Journal
Frontiers in immunology
ISSN: 1664-3224
Titre abrégé: Front Immunol
Pays: Switzerland
ID NLM: 101560960
Informations de publication
Date de publication:
2023
2023
Historique:
received:
08
11
2022
accepted:
19
04
2023
medline:
26
5
2023
pubmed:
24
5
2023
entrez:
24
5
2023
Statut:
epublish
Résumé
Bacterial lipopolysaccharides (LPS) are potent innate immunostimulants targeting the Toll-like receptor 4 (TLR4), an attractive and validated target for immunostimulation in cancer therapy. Although LPS possess anti-tumor activity, toxicity issues prevent their systemic administration at effective doses in humans. We first demonstrated that LPS formulated in liposomes preserved a potent antitumor activity
Identifiants
pubmed: 37223101
doi: 10.3389/fimmu.2023.1066402
pmc: PMC10200957
doi:
Substances chimiques
Adjuvants, Immunologic
0
Cytokines
0
Lipopolysaccharides
0
Liposomes
0
TLR4 protein, human
0
Tlr4 protein, mouse
0
Toll-Like Receptor 4
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1066402Informations de copyright
Copyright © 2023 Chettab, Fitzsimmons, Novikov, Denis, Phelip, Mathé, Choffour, Beaumel, Fourmaux, Norca, Kryza, Evesque, Jordheim, Perrial, Matera, Caroff, Kerzerho and Dumontet.
Déclaration de conflit d'intérêts
KC, AN, JK, and MC are shareholders in HEPHAISTOS-Pharma. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Acta Pharmacol Sin. 2019 Sep;40(9):1168-1183
pubmed: 30858476
Sci Rep. 2013 Oct 16;3:2960
pubmed: 24129891
J Biol Chem. 2002 Dec 6;277(49):47834-43
pubmed: 12324469
J Exp Med. 1978 Dec 1;148(6):1560-9
pubmed: 309922
Lancet. 2007 Jun 30;369(9580):2161-2170
pubmed: 17602732
Cancer Res. 1991 May 15;51(10):2524-30
pubmed: 2021932
J Leukoc Biol. 2010 Dec;88(6):1227-39
pubmed: 20826611
Methods Mol Biol. 2011;739:135-46
pubmed: 21567324
Infect Immun. 1989 Mar;57(3):791-7
pubmed: 2537258
Infect Immun. 1980 Mar;27(3):739-45
pubmed: 6247278
Biochim Biophys Acta. 2016 Apr;1863(4):660-72
pubmed: 26804480
Cells. 2020 Jun 24;9(6):
pubmed: 32599709
Int J Mol Sci. 2021 Jun 29;22(13):
pubmed: 34209703
Oncotarget. 2017 Jul 08;8(39):66656-66667
pubmed: 29029545
Curr Med Chem. 2020;27(17):2887-2901
pubmed: 30362416
Clin Cancer Res. 2019 Feb 15;25(4):1185-1195
pubmed: 30093453
Clin Ther. 2020 Aug;42(8):1519-1534.e33
pubmed: 32739049
Expert Opin Biol Ther. 2019 Jul;19(7):707-720
pubmed: 31081696
Infect Immun. 2000 Nov;68(11):6202-8
pubmed: 11035726
J Cancer Res Clin Oncol. 2014 Nov;140(11):1815-23
pubmed: 24927808
Expert Rev Vaccines. 2007 Apr;6(2):133-40
pubmed: 17408363
Curr Biol. 2017 Jul 24;27(14):2065-2077.e6
pubmed: 28669759
PLoS One. 2013 May 27;8(5):e63967
pubmed: 23724011
Cancer Immunol Immunother. 1996 May;42(4):255-61
pubmed: 8665574
Nanoscale Horiz. 2021 Feb 1;6(2):78-94
pubmed: 33400747
J Clin Invest. 2000 Feb;105(4):497-504
pubmed: 10683379
Cancer Cell Int. 2021 Jul 21;21(1):389
pubmed: 34289846
Cancer Res. 1981 Jul;41(7):2654-7
pubmed: 7018667
Nature. 2019 Oct;574(7776):45-56
pubmed: 31578484
Cells. 2021 Nov 16;10(11):
pubmed: 34831416
J Exp Med. 1997 Jun 16;185(12):2089-94
pubmed: 9182680
Int J Immunopathol Pharmacol. 2013 Oct-Dec;26(4):861-9
pubmed: 24355221
Front Immunol. 2020 Jul 10;11:1210
pubmed: 32765484
Science. 2007 Jun 15;316(5831):1628-32
pubmed: 17569868
Ann Oncol. 2001 Apr;12(4):433-4
pubmed: 11398872
J Cell Biochem. 2019 Mar;120(3):2756-2765
pubmed: 30270458
Neurosurgery. 2001 Mar;48(3):607-14; discussion 614-5
pubmed: 11270552
Leuk Lymphoma. 2022 Apr;63(4):821-833
pubmed: 34865586
Front Immunol. 2014 Jul 10;5:316
pubmed: 25071777
J Pharmacol Exp Ther. 2013 Dec;347(3):599-606
pubmed: 24042160
Proc Natl Acad Sci U S A. 2017 May 16;114(20):E3954-E3963
pubmed: 28461481
MAbs. 2015;7(1):192-8
pubmed: 25523586
Infect Immun. 1970 May;1(5):440-5
pubmed: 16557755
Mol Pharm. 2018 Nov 5;15(11):4777-4800
pubmed: 30226786
Cancer Res. 2019 Jan 1;79(1):159-170
pubmed: 30224373
J Vet Intern Med. 2020 Mar;34(2):653-658
pubmed: 31970837
PLoS One. 2013 Jul 17;8(7):e68671
pubmed: 23874715
PLoS One. 2013 Oct 18;8(10):e76338
pubmed: 24204616
Drug Resist Updat. 2016 Nov;29:90-106
pubmed: 27912846
J Chemother. 2004 Nov;16 Suppl 4:94-7
pubmed: 15688621
J Bacteriol. 1994 Aug;176(16):5156-9
pubmed: 8051033
J Immunol. 2008 Aug 1;181(3):1849-58
pubmed: 18641322
Cancer Res. 2016 Feb 1;76(3):513-6
pubmed: 26772756
J Biol Chem. 2018 Jun 29;293(26):10186-10201
pubmed: 29760187
Sci Rep. 2020 Jul 23;10(1):12273
pubmed: 32703960